Clinical importance of patient-reported outcome measures in severe asthma: results from U-BIOPRED

Roy Meys; Frits M E Franssen; Alex J Van 't Hul; Per S Bakke; Massimo Caruso; Barbro Dahlén; Stephen J Fowler; Thomas Geiser; Peter H Howarth; Ildikó Horváth; Norbert Krug; Annelie F Behndig; Florian Singer; Jacek Musial; Dominick E Shaw; Paolo Montuschi; Anke H Maitland-van der Zee; Peter J Sterk; Graham Roberts; Nazanin Z Kermani; Raffaele A Incalzi; Renaud Louis; Lars I Andersson; Scott S Wagers; Sven-Erik Dahlén; Kian Fan Chung; Ian M Adcock; Martijn A Spruit; The U-Biopred Study Group

doi:10.1186/s12955-024-02321-3

Clinical importance of patient-reported outcome measures in severe asthma: results from U-BIOPRED

Roy Meys, Frits M E Franssen, Alex J Van 't Hul, Per S Bakke, Massimo Caruso, Barbro Dahlén, Stephen J Fowler, Thomas Geiser, Peter H Howarth, Ildikó Horváth, Norbert Krug, Annelie F Behndig, Florian Singer, Jacek Musial, Dominick E Shaw, Paolo Montuschi, Anke H Maitland-van der Zee, Peter J Sterk, Graham Roberts, Nazanin Z KermaniRaffaele A Incalzi, Renaud Louis, Lars I Andersson, Scott S Wagers, Sven-Erik Dahlén, Kian Fan Chung, Ian M Adcock, Martijn A Spruit, The U-Biopred Study Group

Division of Immunology, Immunity to Infection and Respiratory Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

RATIONALE: Knowledge about the clinical importance of patient-reported outcome measures (PROMs) in severe asthma is limited.

OBJECTIVES: To assess whether and to what extent asthma exacerbations affect changes in PROMS over time and asthma-specific PROMs can predict exacerbations in adult patients with severe asthma in usual care.

METHODS: Data of 421 patients with severe asthma (62% female; mean age 51.9 ± 13.4 years; mean FEV 1 67.5 ± 21.3%pred) from the U-BIOPRED cohort were analyzed. The included PROMs were: Asthma Control Questionnaire (ACQ5); Asthma Quality of Life Questionnaire (AQLQ); Hospital Anxiety and Depression scale (HADS); Epworth Sleepiness Scale (ESS); Medication Adherence Report Scale (MARS); Sino-Nasal Outcomes Test (SNOT20). Participants were assessed at baseline and after 12-18 months of usual care.

RESULTS: PROMs showed very weak to weak correlations with clinical characteristics such as age, body mass index, FEV 1, FeNO and eosinophilic cell count. Patients presenting no exacerbations during follow-up showed a statistically significant improvement in all PROMs (except for MARS), whereas individuals experiencing > 2 exacerbations showed a deterioration. Baseline ACQ5 was a predictor of exacerbations with an AUC of 0.590 (95%CI 0.514-0.666).

CONCLUSIONS: The association of PROMs with clinical measures was poor in severe asthmatics. Moreover, PROMs were prone to changes in usual care, with exacerbations playing a key role. PROMs need to be systematically evaluated in severe asthma to improve clinical care based on specific patient's needs.

Original language	English
Pages (from-to)	1-10
Number of pages	10
Journal	Health and Quality of Life Outcomes
Volume	22
Issue number	1
DOIs	https://doi.org/10.1186/s12955-024-02321-3
Publication status	Published - 20 Dec 2024

Keywords

Humans
Asthma/drug therapy
Female
Male
Patient Reported Outcome Measures
Middle Aged
Adult
Quality of Life
Surveys and Questionnaires
Severity of Illness Index
Clinical Relevance

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s12955-024-02321-3

Cite this

Meys, R., Franssen, F. M. E., Van 't Hul, A. J., Bakke, P. S., Caruso, M., Dahlén, B., Fowler, S. J., Geiser, T., Howarth, P. H., Horváth, I., Krug, N., Behndig, A. F., Singer, F., Musial, J., Shaw, D. E., Montuschi, P., Zee, A. H. M. D., Sterk, P. J., Roberts, G., ... The U-Biopred Study Group (2024). Clinical importance of patient-reported outcome measures in severe asthma: results from U-BIOPRED. Health and Quality of Life Outcomes, 22(1), 1-10. https://doi.org/10.1186/s12955-024-02321-3

@article{dd6b10dd5fe641e783636c221912704c,

title = "Clinical importance of patient-reported outcome measures in severe asthma: results from U-BIOPRED",

abstract = "RATIONALE: Knowledge about the clinical importance of patient-reported outcome measures (PROMs) in severe asthma is limited.OBJECTIVES: To assess whether and to what extent asthma exacerbations affect changes in PROMS over time and asthma-specific PROMs can predict exacerbations in adult patients with severe asthma in usual care.METHODS: Data of 421 patients with severe asthma (62% female; mean age 51.9 ± 13.4 years; mean FEV 1 67.5 ± 21.3%pred) from the U-BIOPRED cohort were analyzed. The included PROMs were: Asthma Control Questionnaire (ACQ5); Asthma Quality of Life Questionnaire (AQLQ); Hospital Anxiety and Depression scale (HADS); Epworth Sleepiness Scale (ESS); Medication Adherence Report Scale (MARS); Sino-Nasal Outcomes Test (SNOT20). Participants were assessed at baseline and after 12-18 months of usual care. RESULTS: PROMs showed very weak to weak correlations with clinical characteristics such as age, body mass index, FEV 1, FeNO and eosinophilic cell count. Patients presenting no exacerbations during follow-up showed a statistically significant improvement in all PROMs (except for MARS), whereas individuals experiencing > 2 exacerbations showed a deterioration. Baseline ACQ5 was a predictor of exacerbations with an AUC of 0.590 (95%CI 0.514-0.666). CONCLUSIONS: The association of PROMs with clinical measures was poor in severe asthmatics. Moreover, PROMs were prone to changes in usual care, with exacerbations playing a key role. PROMs need to be systematically evaluated in severe asthma to improve clinical care based on specific patient's needs.",

keywords = "Humans, Asthma/drug therapy, Female, Male, Patient Reported Outcome Measures, Middle Aged, Adult, Quality of Life, Surveys and Questionnaires, Severity of Illness Index, Clinical Relevance",

author = "Roy Meys and Franssen, {Frits M E} and {Van 't Hul}, {Alex J} and Bakke, {Per S} and Massimo Caruso and Barbro Dahl{\'e}n and Fowler, {Stephen J} and Thomas Geiser and Howarth, {Peter H} and Ildik{\'o} Horv{\'a}th and Norbert Krug and Behndig, {Annelie F} and Florian Singer and Jacek Musial and Shaw, {Dominick E} and Paolo Montuschi and Zee, {Anke H Maitland-van der} and Sterk, {Peter J} and Graham Roberts and Kermani, {Nazanin Z} and Incalzi, {Raffaele A} and Renaud Louis and Andersson, {Lars I} and Wagers, {Scott S} and Sven-Erik Dahl{\'e}n and Chung, {Kian Fan} and Adcock, {Ian M} and Spruit, {Martijn A} and {The U-Biopred Study Group}",

note = "{\textcopyright} 2024. The Author(s).",

year = "2024",

month = dec,

day = "20",

doi = "10.1186/s12955-024-02321-3",

language = "English",

volume = "22",

pages = "1--10",

journal = "Health and Quality of Life Outcomes",

issn = "1477-7525",

publisher = "Springer Nature",

number = "1",

}

Meys, R, Franssen, FME, Van 't Hul, AJ, Bakke, PS, Caruso, M, Dahlén, B, Fowler, SJ, Geiser, T, Howarth, PH, Horváth, I, Krug, N, Behndig, AF, Singer, F, Musial, J, Shaw, DE, Montuschi, P, Zee, AHMD, Sterk, PJ, Roberts, G, Kermani, NZ, Incalzi, RA, Louis, R, Andersson, LI, Wagers, SS, Dahlén, S-E, Chung, KF, Adcock, IM, Spruit, MA & The U-Biopred Study Group 2024, 'Clinical importance of patient-reported outcome measures in severe asthma: results from U-BIOPRED', Health and Quality of Life Outcomes, vol. 22, no. 1, pp. 1-10. https://doi.org/10.1186/s12955-024-02321-3

TY - JOUR

T1 - Clinical importance of patient-reported outcome measures in severe asthma

T2 - results from U-BIOPRED

AU - Meys, Roy

AU - Franssen, Frits M E

AU - Van 't Hul, Alex J

AU - Bakke, Per S

AU - Caruso, Massimo

AU - Dahlén, Barbro

AU - Fowler, Stephen J

AU - Geiser, Thomas

AU - Howarth, Peter H

AU - Horváth, Ildikó

AU - Krug, Norbert

AU - Behndig, Annelie F

AU - Singer, Florian

AU - Musial, Jacek

AU - Shaw, Dominick E

AU - Montuschi, Paolo

AU - Zee, Anke H Maitland-van der

AU - Sterk, Peter J

AU - Roberts, Graham

AU - Kermani, Nazanin Z

AU - Incalzi, Raffaele A

AU - Louis, Renaud

AU - Andersson, Lars I

AU - Wagers, Scott S

AU - Dahlén, Sven-Erik

AU - Chung, Kian Fan

AU - Adcock, Ian M

AU - Spruit, Martijn A

AU - The U-Biopred Study Group,

PY - 2024/12/20

Y1 - 2024/12/20

N2 - RATIONALE: Knowledge about the clinical importance of patient-reported outcome measures (PROMs) in severe asthma is limited.OBJECTIVES: To assess whether and to what extent asthma exacerbations affect changes in PROMS over time and asthma-specific PROMs can predict exacerbations in adult patients with severe asthma in usual care.METHODS: Data of 421 patients with severe asthma (62% female; mean age 51.9 ± 13.4 years; mean FEV 1 67.5 ± 21.3%pred) from the U-BIOPRED cohort were analyzed. The included PROMs were: Asthma Control Questionnaire (ACQ5); Asthma Quality of Life Questionnaire (AQLQ); Hospital Anxiety and Depression scale (HADS); Epworth Sleepiness Scale (ESS); Medication Adherence Report Scale (MARS); Sino-Nasal Outcomes Test (SNOT20). Participants were assessed at baseline and after 12-18 months of usual care. RESULTS: PROMs showed very weak to weak correlations with clinical characteristics such as age, body mass index, FEV 1, FeNO and eosinophilic cell count. Patients presenting no exacerbations during follow-up showed a statistically significant improvement in all PROMs (except for MARS), whereas individuals experiencing > 2 exacerbations showed a deterioration. Baseline ACQ5 was a predictor of exacerbations with an AUC of 0.590 (95%CI 0.514-0.666). CONCLUSIONS: The association of PROMs with clinical measures was poor in severe asthmatics. Moreover, PROMs were prone to changes in usual care, with exacerbations playing a key role. PROMs need to be systematically evaluated in severe asthma to improve clinical care based on specific patient's needs.

AB - RATIONALE: Knowledge about the clinical importance of patient-reported outcome measures (PROMs) in severe asthma is limited.OBJECTIVES: To assess whether and to what extent asthma exacerbations affect changes in PROMS over time and asthma-specific PROMs can predict exacerbations in adult patients with severe asthma in usual care.METHODS: Data of 421 patients with severe asthma (62% female; mean age 51.9 ± 13.4 years; mean FEV 1 67.5 ± 21.3%pred) from the U-BIOPRED cohort were analyzed. The included PROMs were: Asthma Control Questionnaire (ACQ5); Asthma Quality of Life Questionnaire (AQLQ); Hospital Anxiety and Depression scale (HADS); Epworth Sleepiness Scale (ESS); Medication Adherence Report Scale (MARS); Sino-Nasal Outcomes Test (SNOT20). Participants were assessed at baseline and after 12-18 months of usual care. RESULTS: PROMs showed very weak to weak correlations with clinical characteristics such as age, body mass index, FEV 1, FeNO and eosinophilic cell count. Patients presenting no exacerbations during follow-up showed a statistically significant improvement in all PROMs (except for MARS), whereas individuals experiencing > 2 exacerbations showed a deterioration. Baseline ACQ5 was a predictor of exacerbations with an AUC of 0.590 (95%CI 0.514-0.666). CONCLUSIONS: The association of PROMs with clinical measures was poor in severe asthmatics. Moreover, PROMs were prone to changes in usual care, with exacerbations playing a key role. PROMs need to be systematically evaluated in severe asthma to improve clinical care based on specific patient's needs.

KW - Humans

KW - Asthma/drug therapy

KW - Female

KW - Male

KW - Patient Reported Outcome Measures

KW - Middle Aged

KW - Adult

KW - Quality of Life

KW - Surveys and Questionnaires

KW - Severity of Illness Index

KW - Clinical Relevance

U2 - 10.1186/s12955-024-02321-3

DO - 10.1186/s12955-024-02321-3

M3 - Article

C2 - 39707320

SN - 1477-7525

VL - 22

SP - 1

EP - 10

JO - Health and Quality of Life Outcomes

JF - Health and Quality of Life Outcomes

IS - 1

ER -

Clinical importance of patient-reported outcome measures in severe asthma: results from U-BIOPRED

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this